FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Clinical trial NCT05432193 · TERMINATED

Trial details

NCT number: NCT05432193
Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma Colorectal Cancer Esophageal Cancer Melanoma (Skin)Soft Tissue Sarcoma Head and Neck Squamous Cell Carcinoma Cholangiocarcinoma

Start date: 2022-07-13
Primary completion: 2023-11-10
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.